Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Statins and Diabetes: Despite Potential Link, Doctors Still Agree On Cholesterol-Lowering Effectiveness

XTALKS VITALS NEWS

Cholesterol

The article takes a strong stance on the issue, arguing that even if the unproven link was verified, the benefits of statins in preventing heart attacks and strokes far outweighs the minor risk of developing diabetes.

Share this!

January 19, 2017 | by Sarah Hand, M.Sc.

A commentary published in The American Journal of Medicine, has attempted to address the possible link between statins – a class of cholesterol-lowing drugs – and diabetes. The article takes a strong stance on the issue, arguing that even if the unproven link was verified, the benefits of statins in preventing heart attacks and strokes far outweighs the minor risk of developing diabetes.

“The totality of evidence clearly indicates that the more widespread and appropriate utilization of statins, as adjuncts, not alternatives to therapeutic lifestyle changes, will yield net benefits in the treatment and primary prevention of heart attacks and strokes, including among high, medium and low risk patients unwilling or unable to adopt therapeutic lifestyle changes,” said Dr. Charles H. Hennekens, professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and one of three authors of the article.



In a related editorial, Dr. Joseph S. Alpert, editor-in-chief of the journal, as well as professor of medicine at the University of Arizona School of Medicine, agrees with the main points of the article and further emphasizes the challenges of treating and preventing heart disease. “There is no threshold for low density lipoprotein cholesterol below which there are no net benefits of statins either in the treatment or primary prevention of heart attacks and strokes,” said Alpert.

According to the authors, the possible risk of developing diabetes could prevent doctors from prescribing the drugs to patients who could benefit from treatment. Similarly, patients may refuse or cease treatment with statins if they are not properly informed of the benefits, potentially leading to an increase in preventable deaths due to heart attacks and strokes.

“These public health issues are especially alarming in primary prevention, particularly among women, for whom cardiovascular disease also is the leading cause of death, and for whom there is even more underutilization of statins than for men,” said Hennekens. In 2013, the American Heart Association published new guidelines for the use of statins which included broader use in both prevention and treatment of heart disease. Heart disease is responsible for around 600,000 US deaths per year, according to the Centers for Disease Control and Prevention (CDC).


Keywords: Statins, Diabetes, Cholesterol


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.